Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm

Allogeneics Still Waiting For Breakthrough

Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors. 

Celyad
Celyad differs from rivals in using a non-gene edited platform for its off-the-shelf CAR-Ts.

Celyad, one of the leaders in developing off-the-shelf CAR-T therapies, is to work with Merck & Co on a new combination targeting a hard-to-treat metastatic colorectal cancer (mCRC) patients. 

Belgium-based Celyad is to shortly to commence a trial of its lead candidate CYAD-101 with Merck & Co.’s blockbuster...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.